RSSCategory: Genetics

Vice President Biden Addresses Attendees at ASCO 2016

| June 7, 2016 | 0 Comments

“This is good news in the fight against cancer. With the launch of this new national resource, anyone can freely access raw genomic and clinical data for 12,000 patients – with more records to follow. Increasing the pool of researchers who can access data and decreasing the time it takes for them to review and […]

Continue Reading

FDA Approves First Liquid Biopsy Test for Use in Non-Small Cell Lung Cancer

| June 1, 2016 | 0 Comments

Exciting news today from FDA with news of approval of first liquid biopsy test for use in non-small cell lung cancer.  The cobas EGFR test is already approved for use in formalin-fixed paraffin-embedded (FFPE) tissue. This new use is intended for detection of these specific mutations in circulating-free tumor DNA (cfDNA) from plasma for first […]

Continue Reading

Mayo Clinic Awarded Funding to Support World’s Largest Research-Cohort Biobank

| May 27, 2016 | 0 Comments

As part of President Obama’s Precision Medicine Initiative (PMI), the National Institutes of Health will award $142 million over five years to the Mayo Clinic, Rochester, Minnesota, to establish the world’s largest research-cohort biobank for the PMI Cohort Program, a longitudinal research study which aims to enroll 1 million or more U.S. participants to advance precision medicine. […]

Continue Reading

Visit Foundation Medicine at ASCO 2016

| May 17, 2016 | 0 Comments

Foundation Medicine will be exhibiting at Booth #24109 during the meeting with over 20 poster presentations and 2 oral presentations at #ASCO16. No doubt that genomic profiling, immunotherapy and liquid biopsy are going to have a huge presence at ASCO and Foundation Medicine is actively involved bringing patient-centric technologies to market for targeted therapies. Foundation Medicine is […]

Continue Reading

FDA Grants Accelerated Approval to Nivolumab in Classical Hodgkin Lymphoma

| May 17, 2016 | 0 Comments

More interesting news around PD-L1 for use in Classical Hodgkin lymphoma with specific indications as below. Another increasingly common example of companion diagnostics and personalized immunotherapies. On May 17, 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients with classical Hodgkin lymphoma that has […]

Continue Reading

Register Now for Webinar: Pathology Drives Cancer Moonshot Initiative

| April 19, 2016 | 0 Comments

REGISTER NOW! Since the Moonshot hit Congress, how can pathologists and other clinicians play a more significant role in the war on cancer? Changes in the way healthcare is delivered are driving the industry aggressively toward more cost effective, value-based care models. Technology that enables the delivery of medicine in this new paradigm connects healthcare […]

Continue Reading

In Pursuit of Patient-Centered Care

| March 29, 2016 | 0 Comments

Enhancing the patient experience through a patient-centered approach to care is a growing priority for healthcare organizations. The primary objective of patient-centered care is to ensure a continuing relationship between the patient and his or her healthcare team with a focus on prevention and detection, diagnostic accuracy, and team-based, multi-disciplinary information sharing and collaboration. Improving […]

Continue Reading

Cynvenio Announces Availability of Concordia, a New Cell-free DNA Purification Upgrade for its LiquidBiopsy Whole Blood Enrichment Platform

| February 23, 2016 | 0 Comments

Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients, recently announced the availability of the ConcordiaT cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsyR platform. When coupled with Thermo Fisher Scientific’s Ion TorrentT next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell […]

Continue Reading

Man on The Moon

| January 13, 2016 | 0 Comments

I don’t usually make political statements on this blog and don’t plan on doing so anytime soon. In fact, I have little interest at the moment and 2-year presidential election cycles and endless coverage of every detail of the professional and personal lives of candidates and elected officials. Having said that, I watched the State […]

Continue Reading

UK NEQAS for Molecular Genetics Selects PathXL Software to Support Molecular Pathology EQA Scheme

| November 29, 2015 | 0 Comments

United Kingdom National External Quality Assessment Service (UK NEQAS) for Molecular Genetics choose PathXL digital pathology software to run a national scheme to assess consistency of tumour analysis for molecular pathology testing, as part of ensuring the high quality standard of Genomics England 100,000 Genome Project. Belfast, Northern Ireland, November 30, 2015 — PathXL are […]

Continue Reading

ASI Partners with ScreenCell to Develop a Novel, Non-Invasive Prenatal Diagnosis Based on Circulating Fetal Cells 

| November 4, 2015 | 0 Comments

Partnership is intended to overcome limitations of existing methods, widening the range of genetic abnormalities that can be screened.  Carlsbad CA, US and Sarcelles, FRANCE – November 4, 2015 – Applied Spectral Imaging (ASI, and ScreenCell announced today that they have entered into a global partnership to develop a procedure enabling genetic analysis of […]

Continue Reading

Philips and Genomic Health Announce Digital Pathology Partnership

| October 13, 2015 | 0 Comments

Interesting news yesterday from Philips and Genomic Health announcing a collaboration of their technologies. For many years I have thought one of the main drivers for digital pathology adoption in an increasing trend towards personalized, predictive and pre-emptive medicine would be the need for a bridge between morphology and molecular.  Often times the paraffin block […]

Continue Reading

Foundation Medicine Expands Molecular Information Decision Support Offerings with GeneKit™, a Genomic Solutions Portal for Pathologists

| September 21, 2015 | 0 Comments

Powered by FoundationCORE™, GeneKit Enables Unmatched Interpretation, Analysis and Reporting of Genomic Data into Clinical Practice CAMBRIDGE, Mass.– Foundation Medicine, Inc. (NASDAQ:FMI) recently announced the expansion of its suite of molecular information-based products with GeneKitTM, a genomics solutions portal for pathologists. Uniquely differentiated by the power of FoundationCORETM, Foundation Medicine’s ever-growing comprehensive cancer genomics knowledgebase of more […]

Continue Reading

Roche to acquire Kapa Biosystems to strengthen next-generation sequencing product offerings

| September 7, 2015 | 0 Comments

Roche (SIX: RO, ROG; OTCQX: RHHBY) recently announced that it has signed a definitive agreement to acquire Kapa Biosystems, Inc. (Kapa) a privately-held company headquartered in Wilmington, Massachusetts. US. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well […]

Continue Reading